01952.HK
Everest Medicines Limited
HKSE · Healthcare · Biotechnology · CN
HKD 27.02
−9.27%Year over year
Reported trailing growth
- Revenue
- +182.9%
- EBITDA
- +123.8%
- EBIT
- +83.3%
- EPS
- +92.2%
- Free cash flow
- -36.9%
- Operating cash flow
- -1.2%
Forward estimates
Based on analyst estimates
- Revenue
- -20.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +411.0%
- EBITDA
- +71.0%
- EBIT
- +65.4%
- Net income
- +71.4%
- EPS
- +72.5%
- Free cash flow
- +76.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026